Celik S.Yalcın M.Z.Kılıc O.Tan M.Kalcioglu M.T.2024-08-042024-08-0420241308-7649https://doi.org/10.5152/iao.2024.231208https://hdl.handle.net/11616/91565BACKGROUND: Although advanced technologies and surgical procedures are used, cholesteatoma is a disease with the possibility of recurrence. The aim of this study was to determine the long-term effect of sodium 2-mercaptoethane sulfonate (MESNA) on cholesteatoma surgery. METHODS: Patients who underwent cholesteatoma surgery between January 2009 and July 2014 by the same surgeon were divided into 2 groups: those where MESNA was used and those where it was not. Otomicroscopic examinations were performed to see the presence of cholesteatoma recurrence in the patients who had surgery at least 8 years ago. Pure-tone audiometry was performed to evaluate the hearing results. RESULTS: Sodium 2-mercaptoethane sulfonate was used in 23 patients and was not used in 39 patients who came to the control. In the MESNA-used group, cholesteatoma was seen in only 1 of the patients who underwent a canal wall-down (CWD) mastoidectomy. In the MESNA non-used group, cholesteatoma was seen in 3 patients who underwent CWD. The difference was not statistically significant. CONCLUSION: Although there was no statistically significant difference, recurrence of cholesteatoma was seen less frequently in patients who received MESNA during surgery. Studies to be conducted in larger patient series may clarify this issue. © 2024, AVES. All rights reserved.eninfo:eu-repo/semantics/closedAccessCholesteatomamastoidectomyMESNAArticle20323123510.5152/iao.2024.2312082-s2.0-85195285052Q3